GEOVAX LABS, INC. (OTCMKTS:GOVX) Files An 8-K Results of Operations and Financial Condition

GEOVAX LABS, INC. (OTCMKTS:GOVX) Files An 8-K Results of Operations and Financial Condition
Item 2.02

Story continues below

Results of Operations and Financial Condition

On March 27, 2019 we issued a press release reporting our results of operations for the year ended December 31, 2018. A copy of the press release is attached to this Current Report.

Item 9.01

Financial Statements and Exhibits

Exhibit 99.1

Press Release

GeoVax Labs, Inc. Exhibit
EX-99.1 2 ex_139002.htm EXHIBIT 99.1 ex_139002.htm Exhibit 99.1     GeoVax Reports 2018 Year-End Financial Results   ATLANTA,…
To view the full exhibit click here


GeoVax Labs, Inc. (GeoVax) is a clinical-stage biotechnology company. The Company is engaged in developing human vaccines against infectious diseases using its modified vaccine Ankara-virus-like particles (MVA-VLP) vaccine platform. The Company’s platform supports in vivo expression of non-infectious virus-like particles (VLPs) from the cells of the person receiving the vaccine. The Company’s development programs are focused on vaccines against Human Immunodeficiency Virus (HIV), Zika virus and hemorrhagic fever viruses (Ebola, Marburg and Lassa Fever), as well as for use in cancer immunotherapy. The Company’s clinically advanced vaccine development program is a (deoxyribonucleic acid (DNA)/MVA) vaccine regimen designed to protect against the clade B subtype of the HIV virus. The Company is developing a Tetravalent Vaccine (TV) utilizing its MVA-VLP platform to address the unmet need for a product that can respond to future filovirus epidemics.

An ad to help with our costs